Dupilumab Demonstrates Rapid Onset of Action in Improving Signs, Symptoms and Quality of Life in Adults with Atopic Dermatitis

INTRODUCTION: Dupilumab has significantly improved the signs, symptoms and quality of life (QoL) of patients with moderate-to-severe atopic dermatitis (AD) in randomised, controlled clinical trials. However, there is a need to assess the effectiveness and safety of dupilumab in real-world clinical p...

Descripción completa

Detalles Bibliográficos
Autores principales: Augustin, Matthias, Bauer, Andrea, Ertner, Konstantin, von Kiedrowski, Ralph, Schenck, Florian, Ramaker-Brunke, Jutta, Möller, Sophie, Fait, Anja, Bastian, Mike, Thaçi, Diamant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984619/
https://www.ncbi.nlm.nih.gov/pubmed/36738405
http://dx.doi.org/10.1007/s13555-023-00894-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984619/
https://www.ncbi.nlm.nih.gov/pubmed/36738405
http://dx.doi.org/10.1007/s13555-023-00894-3

Ejemplares similares